Inhibitors of human plasmin derived from the Kunitz domains

Details Inhibitors of human plasmin derived from the Kunitz domains Inhibitors of human plasmin derived from the Kunitz domains

2011-04-05

2011-04-05

Robinson, Hope A (Department: 1652)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C435S258100, C435S069200, C530S350000

Reexamination Certificate

active

07919462

ABSTRACT:
This invention features novel proteins that are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and are capable of inhibiting plasmin and nucleic acids encoding these proteins. The invention also features the use of such proteins in therapeutic, diagnostic, and clinical methods.

REFERENCES:
patent: 4118481 (1978-10-01), Schnabel et al.
patent: 4153687 (1979-05-01), Schnabel et al.
patent: 4595674 (1986-06-01), Tschesche et al.
patent: 4657893 (1987-04-01), Krantz et al.
patent: 4845242 (1989-07-01), Powers et al.
patent: 5118668 (1992-06-01), Auerswald et al.
patent: 5166133 (1992-11-01), Houston et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5278144 (1994-01-01), Wolf et al.
patent: 5278285 (1994-01-01), Ebbers et al.
patent: 5373090 (1994-12-01), Norris et al.
patent: 5407915 (1995-04-01), Fritz et al.
patent: 5409895 (1995-04-01), Morishita et al.
patent: 5576294 (1996-11-01), Norris et al.
patent: 5583107 (1996-12-01), Wolf et al.
patent: 5589359 (1996-12-01), Innis et al.
patent: 5677146 (1997-10-01), Sprecher et al.
patent: 5719041 (1998-02-01), Lazarus et al.
patent: 5736364 (1998-04-01), Kelley et al.
patent: 5770568 (1998-06-01), Auerswald et al.
patent: 5780265 (1998-07-01), Denis et al.
patent: 5786328 (1998-07-01), Denis et al.
patent: 5795865 (1998-08-01), Markland et al.
patent: 5795954 (1998-08-01), Lazarus et al.
patent: 5843895 (1998-12-01), Lazarus et al.
patent: 5994125 (1999-11-01), Markland et al.
patent: 6004579 (1999-12-01), Bathurst et al.
patent: 6010880 (2000-01-01), Markland et al.
patent: 6057287 (2000-05-01), Markland et al.
patent: 6071723 (2000-06-01), Markland et al.
patent: 6103499 (2000-08-01), Markland et al.
patent: 6333402 (2001-12-01), Markland et al.
patent: 6423498 (2002-07-01), Markland et al.
patent: 6953674 (2005-10-01), Markland et al.
patent: 2004/0038893 (2004-02-01), Ladner et al.
patent: 2004/0053206 (2004-03-01), Cicardi et al.
patent: 0 132 732 (1985-02-01), None
patent: 0 307 592 (1989-03-01), None
patent: 0 486 001 (1992-05-01), None
patent: WO 90/02809 (1990-03-01), None
patent: WO 93/14120 (1993-07-01), None
patent: WO 93/14121 (1993-07-01), None
patent: WO 93/14122 (1993-07-01), None
patent: WO 95/18830 (1995-07-01), None
patent: WO 95/21601 (1995-08-01), None
CAA27063 (gi1364184): “unnamed protein product [Bos taurus]”, GenBank Record dated Nov. 17, 2004, (GenBank [online] Bethesda, MD USA: United States National Library of Medicine, retrieved on Dec. 1, 2004, retrieved from internet using <URL:www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Protein&list—uids=013...>, GenBank Acession No. CAA27063 (gi1364184).
Chen et al., “Refined 2•5 Å X-ray Crystal Structure of the Complex Formed by Porcine Kallikrein A and the Bovine Pancreatic Trypsin Inhibitor”, J. Mol. Biol., (1983), 164, 283-311.
International Preliminary Examination Report dated Apr. 25, 1996 from International Application No. PCT/US95/00298.
International Search Report dated Jul. 4, 1995 from International Application No. PCT/US95/00298.
Written Opinion dated Feb. 6, 1996 from International Application No. PCT/US95/00298.
Moroi et al., “Isolation and Characterization of α2-Plasmin Inhibitor from Human Plasma”, J. Biological Chemistry, (1976), 251(19), 5956-5965.
Petersen et al. “Binding of bovine pancreatic trypsin inhibitor to heparin binding protein/CAP37/azurocidin”, Eur., J. Biochem., (1993), 214(1), 271-279.
Sartor et al., “Selective Kallikrein-Kinin System Activation in Inbred Rats Differentially Susceptible to Granulomatous Enterocolitis”, Gastroenterology, (1996), 110, 1467-1481.
Stadnicki et al., “Selective Plasma Kallikrein Inhibitor Attenuates Acute Intestinal Inflammation in Lewis Rat”, Digestive Diseases and Sciences, (1996), 41(5), 912-920.
Tuddenham et al., “Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition”, Nucleic Acids Research, (1994), 22(17), 3511-3533.
Adelman et al., Blood, 68(6):1280-1284 (1986).
Albrecht, G.J., et al., “Kunitz-Type Proteinase Inhibitors Derived by Limited Proteolysis of the Inter-α-Trypsin Inhibitors, IX[1-8],” Hoppe-Seyler'sZ. Physiol.Chem., 364:1697-1702 (1983).
Anba et al., Biochimie, 70(6):727-733 (1988).
Angliker, H., et al., “The Synthesis of Lysylfluoromethanes and Their Properties as Inhibitors of Trypsin, Plasmin and Cathepsin B,”Biochem J., 241:871-875 (1987).
Auerswald et al., Bio. Chem. Hoppe-Seyler, 369(Suppl):27-35 (1988).
Baba, M. et al., “States of Tyrosyl Residues and Circular Dichroism of Kunitz Trypsin Inhibitor,”J. Biochem. (Tokyo), 65(1):113-121 (1969).
Baneyx & Georgiou, J. Bacteriol., 173(8):2696-2703 (1991).
Baneyx and Georgiou, J. Bacteriol., 172(1):491-494 (1990).
Beckmann, J., et al., “Preparation of Chemically ‘Mutated’ Aprotinin Homologues by Semisynthesis-P1Substitutions Change Inhibitory Specificity,”Eur. J. Biochem., 176: 675-682 (1988).
Brinkmann, T., and Tschesche, H., “Design of an Aprotinin Variant with Inhibitory Activity Against Chymotrypsin and Cathepsin G by Recombinant DNA Technology”,Biol. Chem. Hoppe-Seyler, vol. 371, pp. 43-52. 1990.
Browne et al., GeneBank, Accession No. M74220 (1991).
Broze et al., Biochemisty, 29(33):7539-7546 (1990).
Chen, C., et al., “Solution Structure of a Kunitz-type Chymotrypsin Inhibitor Isolated from the Elapid SnakeBungarus fasciatus,” J. Biol. Chem., 276:45079-45087 (2001).
Colman et al., Hemostasis and Thrombosis, Second Edition (Colman et al., eds; ISBN 0-397-50679-1) Chap. 1, pp. 3-17 (1987).
Dennis and Lazarus, J. Biological Chem., 269(35):22129-22136 (1994).
Dennis and Lazarus, J. Biological Chem., 269(35):22137-22144 (1994).
Dennis, M.S. et al., “Potent and Selective Kunitz-Domain Inhibitors of Plasma Kallikrein Designed by Phage Display”,J. Biol. Chem., vol. 270, pp. 25411-25417, 1995.
Dufton, M.J., “Proteinase Inhibitors and Dendrotoxins,”Eur. J. Biochem, 153:647-654 (1985).
Eigenbrot et al., Protein Engineering, 3(7):591-598 (1990).
Ellis et al., Ann. NY Acad. Sci., 667:13-31 (1992).
Fidler and Ellis, Cell, 79:185-188 (1994).
Fraedfich et al., Thorac. Cardiovasc. Surg., 37(2):89-91 (1989).
Ganu, V.S., et al., “Improved Synthetic Inactivators of Plasmin,”Thromb. Res., 45:1-6 (1987).
Gardell, Toxicol. Pathol., 21(2):190-198 (1993).
Girard et al., J. Biol. Chem., 266(8):5036-5041 (1991).
Girard et al., Nature, 338:518-20 (1989).
Goldenberg, D.P., and Creighton, T.E., “Circular and Circularly Permuted Forms of Bovine Pancreatic Trypsin Inhibitor,”J. Mol. Biol., 165:407-13 (1983).
Greg et al., Bio/Technology, 11:905-910 (1993).
Hoover et al., Biochemistry, 32:10936-10943 (1993).
Hynes et al., Biochemistry, 29:10018-10022 (1990).
Kido et al., Biochem. & Biophys. Res. Comm., 167(2):716-721 (1990).
Kido et al., J. Biol. Chem., 263(34):18104-18107 (1988).
Kurjan and Herkowwitz, Cell, 30:933-943 (1982).
Laskowski and Kato, Ann. Rev. Biochem., 49:593-626 (1980).
Leatherbarrow and Salacinski, Biochemistry, 30(44):1071710721 (1991).
Ley, A.C. et al., “Obtaining a Family of High-Affinity, High-Specificity Protein Inhibitors of Plasmin and Plasma Kallikrein”,Molecular Diversity, vol. 2, pp. 119-124, 1996.
Lohmann and Marshall, Refract. Corneal. Surg. 9(4):300-302 (1993).
Lucas et al., J. Biological Chem., 258(7):4249-4256 (1983).
Mann and Lundblad, Hemostasis and Thrombosis, Second Edition (Colman et al., eds; ISBN 0-397-50679-1) Chap 10, pp. 148-161 (1987).
Markland J. Cell. Biochem. Supp. O 18D:157, Abstract S 331 (1994).
Markland, B.L., et al., “Selection for Protease Inhibitors Using the Bacteriophage-Display Technology,” Keystone Symposium on Structural and Molecular Biology of Protease Function and Inhibition, Santa Fe, New Mexico, USA, Mar. 5-12, 1994,J. Cell

Affiliated with

Also associated with

Rating

Inhibitors of human plasmin derived from the Kunitz domains does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of human plasmin derived from the Kunitz domains, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of human plasmin derived from the Kunitz domains will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2664110